NIH Helping to End Addiction Long-term (HEAL) Initiative - Funding Opportunities Summary

Information about the funding opportunities listed below follows, including links to the full requests for proposals.

- America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional)
- America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R41/R42 - Clinical Trial Optional)
- Analytical and/or Clinical Validation of a Candidate Biomarker for Pain (R61/R33 Clinical Trial Optional)
- Announcement of the NCATS ASPIRE Design Challenges to Develop Innovative and Catalytic Approaches Towards Solving the Opioid Crisis
- Antenatal Opioid Exposure Longitudinal Study Consortium (PL1 Clinical Trials Not Allowed)
- Back Pain Consortium (BACPAC) Research Program: Mechanistic Research Centers (U19) (Clinical Trial Optional)
- Back Pain Consortium (BACPAC) Research Program Data Integration, Algorithm Development and Operations Management Center (U24) (Clinical Trial Not Allowed)
- Back Pain Consortium (BACPAC) Research Program Technology Research Sites (UH2/UH3) (Clinical Trial Optional)
- Behavioral Research to Improve MAT: Behavioral and Social Interventions to Improve Adherence to Medication Assisted Treatment for Opioid Use Disorders (R61/R33, Clinical Trials Optional)
- Biofabricated 3D Tissue Models of Nociception, Opioid Use Disorder and Overdose for Drug Screening (UH2/UH3 – Clinical Trial Not Allowed)
- Clinical Devices to Treat Pain (UH3 Clinical Trial Optional)
- Coordinating Center to Support NIDA Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 16–30) Initiative (U24 Clinical Trial Not Allowed)
- Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
- Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R21 Clinical Trial Not Allowed)
- Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)
- Discovery of Biomarkers, Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional)
- Early Phase Pain Investigation Clinical Network - Clinical Coordinating Center (U24 Clinical Trial Required)
- Early Phase Pain Investigation Clinical Network - Data Coordinating Center (U24 Clinical Trials Not Allowed)
- Early Phase Pain Investigation Clinical Network - Specialized Clinical Centers (U24 Clinical Trials Not Allowed)
- Effectiveness Trials to Optimize, Implement, Scale, and Sustain the Collaborative Care Model for Individuals with Opioid Use Disorders and Mental Health Conditions (U01 Clinical Trials Required)
- Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
- Integrated Approach to Pain and Opioid Use in Hemodialysis Patients: The Hemodialysis Opioid Prescription Effort (HOPE) Consortium - Clinical Centers (U01 Clinical Trial Required)
- Integrated Approach to Pain and Opioid Use in Hemodialysis Patients: The Hemodialysis Opioid Prescription Effort (HOPE) Consortium - Scientific and Data Research Center (U01 Clinical Trial Required)
- Justice Community Opioid Innovation Network (JCOIN) Methodology and Advanced Analytics Resource Center (U2C Clinical Trial Not Allowed)
- Justice Community Opioid Innovation Network (JCOIN) Coordination and Translation Center (U2C Clinical Trial Optional)
- Justice Community Opioid Innovation Network (JCOIN) Clinical Research Centers (UG1 Clinical Trial Optional)
- Limited Competition: Behavioral Research to Improve MAT: Ancillary Studies to Enhance Behavioral or Social Interventions to Improve Adherence to Medication Assisted Treatment for Opioid Use Disorders (R01, Clinical Trials Optional)
- NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
- Optimization of Non-addictive Therapies [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Not Allowed)
• Optimization of Non-addictive Therapies [Small Molecules and Biologics] to Treat Pain - (U44 Clinical Trial Not Allowed)
• Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
• Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing (PRISM) (UG3/UH3, Clinical Trial Optional)
• Pragmatic Randomized Controlled Trial of Acupuncture for Management of Chronic Low Back Pain in Older Adults (UG3/UH3 Clinical Trial Required)
• Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 16–30) (UG3/UH3 Clinical Trial Required)
• Request for Administrative Supplements to Existing Grants to Accelerate Research on Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 16-30)
• Sleep and Circadian-Dependent Mechanisms Contributing to Opiate Use Disorder (OUD) and Response to Medication Assisted Treatment (MAT) (R01 - Clinical Trial Not Allowed)
• Sleep and Circadian-Dependent Mechanisms Contributing to Opiate Use Disorder (OUD) and Response to Medication Assisted Treatment (MAT) (U01 Clinical Trial Optional)
• Stimulating Peripheral Activity to Relieve Conditions (SPARC): Anatomical and Functional Mapping of Pain-Related Visceral Organ Neural Circuitry (U01 Clinical Optional)
• Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01 Clinical Trial Optional)
• Tissue Chips to Model Nociception, Addiction, and Overdose (UG3/UH3 Clinical Trial Not Allowed)
• Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed)
• Translational Devices to Treat Pain (UG3/UH3 Clinical Trial Optional)
• Translational Devices to Treat Pain (U44 Clinical Trial Optional)

America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional)
Notice Number: RFA-DA-19-019
Letter of Intent Deadline: 30 days prior to the application due date
Application Deadline: January 8, 2019; April 9, 2019; September 8, 2019; April 9, 2020; September 8, 2020; April 9, 2021; September 8, 2021
Summary: Invites eligible small business concerns to submit Small Business Innovation Research (SBIR) grant applications to develop technologies to provide science- and research-based solutions to the national opioid emergency and offer new hope for individuals, families, and communities affected by this devastating crisis.

America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R41/R42 - Clinical Trial Optional)
Notice Number: RFA-DA-19-020
Letter of Intent Deadline: 30 days prior to the application due date
Application Deadline: January 8, 2019; April 9, 2019; September 8, 2019; April 9, 2020; September 8, 2020; April 9, 2021; September 8, 2021
Summary: Invites eligible small business concerns to submit Small Business Technology Transfer (STTR) grant applications to develop technologies to provide science- and research-based solutions to the national opioid emergency and offer new hope for individuals, families, and communities affected by this devastating crisis.

Analytical and/or Clinical Validation of a Candidate Biomarker for Pain (R61/R33 Clinical Trial Optional)
Notice Number: RFA-NS-18-046
Letter of Intent Deadline: 30 days prior to the application due date
Application Deadline: March 7, 2019; November 25, 2019; March 12, 2020
Summary: Promotes the validation of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials.
Announcement of the NCATS ASPIRE Design Challenges to Develop Innovative and Catalytic Approaches Towards Solving the Opioid Crisis

Notice Number: NOT-TR-18-031
Submission Period: December 21, 2018, to May 31, 2019
Summary: The goal is to develop innovative and catalytic approaches towards solving the opioid crisis through development of: 1) novel chemistries; 2) data-mining and analysis tools and technologies; and 3) biological assays that will revolutionize discovery, development and pre-clinical testing of next generation, safer and non-addictive analgesics to treat pain, as well as new treatments for opioid use disorder and overdose.

Antenatal Opioid Exposure Longitudinal Study Consortium (PL1 Clinical Trials Not Allowed)
Notice Number: RFA-HD-19-025
Letter of Intent Deadline: 30 days prior to the application due date
Application Deadline: March 29, 2019
Summary: Invites applications from consortia composed of a Data Coordinating Center and two or more Clinical Sites to conduct a multi-center prospective cohort study of infants exposed to opioids in utero compared to unexposed infants.

Back Pain Consortium (BACPAC) Research Program: Mechanistic Research Centers (U19) (Clinical Trial Optional)
Notice Number: RFA-AR-19-026
Letter of Intent Deadline: February 20, 2019
Application Deadline: March 20, 2019
Summary: Invites applications to plan and implement Interdisciplinary Mechanistic Research Centers in Low Back Pain with the NIH Back Pain Consortium Research Program.

Back Pain Consortium (BACPAC) Research Program Data Integration, Algorithm Development and Operations Management Center (U24) (Clinical Trial Not Allowed)
Notice Number: RFA-AR-19-027
Letter of Intent Deadline: February 20, 2019
Application Deadline: March 20, 2019
Summary: Invites applications for the NIH Back Pain Consortium’s Research Program Data Integration, Algorithm Development and Operations Management Center.

Limited Submission: This is a limited submission funding opportunity. UAB may submit a single response to this RFA. If you wish to prepare a proposal on behalf of UAB, please contact Kent Keyser, Associate Vice President for Research (ktkeyser@uab.edu or 205-934-7757) or Nathan Meier, Director of Research Development (nmeier@uab.edu or 205-934-0934) by January 11, 2019.

Back Pain Consortium (BACPAC) Research Program Technology Research Sites (UH2/UH3) (Clinical Trial Optional)
Notice Number: RFA-AR-19-028
Letter of Intent Deadline: February 20, 2019
Application Deadline: March 20, 2019
Summary: Invites applications for the Technology Research Site component of the NIH Back Pain Consortium Research Program.

Back Pain Consortium (BACPAC) Research Program: Phase 2 Clinical Trials (UG3/UH3) (Clinical Trial Required)
Notice Number: RFA-AR-19-029
Letter of Intent Deadline: January 26, 2019
Application Deadline: February 26, 2019
Summary: Invites research applications to plan and implement Phase 2 clinical trials in chronic Low Back Pain (cLBP) with the NIH Back Pain Consortium Research Program.
Behavioral Research to Improve MAT: Behavioral and Social Interventions to Improve Adherence to Medication Assisted Treatment for Opioid Use Disorders (R61/R33, Clinical Trials Optional)

**Notice Number:** RFA-AT-19-006  
**Letter of Intent Deadline:** January 8, 2019  
**Application Deadline:** February 8, 2019  
**Summary:** Seeks applications to examine the impact of behavioral and social interventions designed to improve adherence to medication assisted treatment for persons with opioid use disorders.

Biofabricated 3D Tissue Models of Nociception, Opioid Use Disorder and Overdose for Drug Screening (UH2/UH3 – Clinical Trial Not Allowed)

**Notice Number:** RFA-TR-19-005  
**Letter of Intent Deadline:** January 28, 2019  
**Application Deadline:** February 28, 2019  
**Summary:** Supports intramural-extramural collaborations to develop and implement the use of 3D biofabricated tissue models as novel drug screening platforms and advance pre-clinical discovery and development of non-addictive treatments for nociception, opioid use disorder and/or overdose.

Clinical Devices to Treat Pain (UH3 Clinical Trial Optional)

**Notice Number:** RFA-NS-19-018  
**Letter of Intent Deadline:** 30 days prior to the application receipt date  
**Application Deadline:** January 9, 2019; March 22, 2019; June 21, 2019; October 21, 2019; February 21, 2020; June 22, 2020; October 21, 2020; February 21, 2021  
**Summary:** Encourages investigators to pursue a small clinical trial to obtain critical information necessary to advance recording and/or stimulating devices to treat pain with innovative, targeted, and non-addictive diagnostic and/or therapeutic devices that improve patient outcomes and decrease or eliminate the need to prescribe opioids.

Coordinating Center to Support NIDA Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 16–30) Initiative (U24 Clinical Trial Not Allowed)

**Notice Number:** RFA-DA-19-034  
**Letter of Intent Deadline:** 30 days prior to the application due date  
**Application Deadline:** March 13, 2019  
**Summary:** Seeks cooperative agreement applications to participate in the HEAL Preventing Opioid Misuse and Opioid Use Disorder in Older Adolescents and Young Adults (ages 16-30) initiative administered by NIDA.

Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)

**Notice Number:** RFA-DA-19-002  
**Letter of Intent Deadline:** 30 days prior to the application due date  
**Application Deadline:** Beginning January 25, 2018, applications submitted in response to this RFA will be received on a rolling basis. The RFA expires on January 2, 2020.  
**Summary:** Supports the discovery and development of medications to prevent and treat opioid use disorders and overdose.

Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R21 Clinical Trial Not Allowed)

**Notice Number:** RFA-NS-18-042  
**Letter of Intent Deadline:** 30 days prior to the application due date  
**Application Deadline:** February 11, 2019; July 11, 2019; November 12, 2019  
**Summary:** Supports exploratory and developmental research projects by providing support for the early and conceptual stages of pain target discovery and validation projects.
Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)

Notice Number: RFA-NS-18-043
Letter of Intent Deadline: 30 days prior to the application due date
Application Deadline: February 11, 2019; July 11, 2019; November 12, 2019
Summary: Promotes the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics.

Discovery of Biomarkers, Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional)

Notice Number: RFA-NS-18-041
Letter of Intent Deadline: 30 days prior to the application due date
Application Deadline: March 7, 2019; November 25, 2019; March 12, 2020
Summary: Promotes the discovery of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials.

Early Phase Pain Investigation Clinical Network - Clinical Coordinating Center (U24 Clinical Trial Required)

Notice Number: RFA-NS-19-023
Letter of Intent Deadline: 30 days prior to the application due date
Application Deadline: February 6, 2019
Summary: Invites applications for the Clinical Coordinating Center (CCC) of the Early Phase Pain Investigation Clinical Network.

Limited Submission: This is a limited submission funding opportunity. UAB may submit a single response to this RFA. If you wish to prepare a proposal on behalf of UAB, please contact Kent Keyser, Associate Vice President for Research (ktkeyser@uab.edu or 205-934-7757) or Nathan Meier, Director of Research Development (nmeier@uab.edu or 205-934-0934) by January 2, 2019.

Early Phase Pain Investigation Clinical Network - Data Coordinating Center (U24 Clinical Trials Not Allowed)

Notice Number: RFA-NS-19-024
Letter of Intent Deadline: 30 days prior to the application due date
Application Deadline: February 6, 2019
Summary: Invites applications for the Data Coordinating Center (DCC) of the Early Phase Pain Investigation Clinical Network.

Limited Submission: This is a limited submission funding opportunity. UAB may submit a single response to this RFA. If you wish to prepare a proposal on behalf of UAB, please contact Kent Keyser, Associate Vice President for Research (ktkeyser@uab.edu or 205-934-7757) or Nathan Meier, Director of Research Development (nmeier@uab.edu or 205-934-0934) by January 2, 2019.

Early Phase Pain Investigation Clinical Network - Specialized Clinical Centers (U24 Clinical Trials Not Allowed)

Notice Number: RFA-NS-19-025
Letter of Intent Deadline: 30 days prior to the application due date
Application Deadline: February 6, 2019
Summary: Invites applications for the Specialized Clinical Centers (“hubs”) of the Early Phase Pain Investigation Clinical Network.

Limited Submission: This is a limited submission funding opportunity. UAB may submit a single response to this RFA. If you wish to prepare a proposal on behalf of UAB, please contact Kent Keyser, Associate Vice President for Research (ktkeyser@uab.edu or 205-934-7757) or Nathan Meier, Director of Research Development (nmeier@uab.edu or 205-934-0934) by January 2, 2019.
Effectiveness Trials to Optimize, Implement, Scale, and Sustain the Collaborative Care Model for Individuals with Opioid Use Disorders and Mental Health Conditions (U01 Clinical Trials Required)

Notice Number: RFA-MH-19-525
Letter of Intent Deadline: March 1, 2019
Application Deadline: April 1, 2019
Summary: Invited applications for effectiveness clinical trials to develop, optimize, implement, scale, and sustain collaborative models that offer Medication Assisted Treatment for opioid use disorders alongside indicated treatment for mental health conditions that commonly co-occur with opioid use disorders and are treatable in primary care.

Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)

Notice Number: PAR-18-219
Letter of Intent Deadline: 30 days prior to the application due date
Application Deadline: March 27, 2019 and July 25, 2019
Summary: Seeks to accelerate the development of medication for the treatment of substance-use disorders by encouraging research applications to support a diverse array of preclinical and/or clinical research projects.

Integrated Approach to Pain and Opioid Use in Hemodialysis Patients: The Hemodialysis Opioid Prescription Effort (HOPE) Consortium - Clinical Centers (U01 Clinical Trial Required)

Notice Number: RFA-DK-18-030
Letter of Intent Deadline: February 27, 2019
Application Deadline: March 27, 2019
Summary: Seeks applications for a consortium composed of a Scientific and Data Research Center and five to seven Clinical Centers to develop an intervention to simultaneously address the problem of pain and opioid use in U.S. hemodialysis patient populations by a) initiating multipronged pain treatment tailored individually to each patient, without opioids, and b) using buprenorphine and other novel agents to reduce dependence on opioids in affected patients.

Integrated Approach to Pain and Opioid Use in Hemodialysis Patients: The Hemodialysis Opioid Prescription Effort (HOPE) Consortium - Scientific and Data Research Center (U01 Clinical Trial Required)

Notice Number: RFA-DK-18-031
Letter of Intent Deadline: February 27, 2019
Application Deadline: March 27, 2019
Summary: Seeks applications for a Scientific and Data Research Center to support a consortia of five to seven Clinical Centers that will develop an intervention to simultaneously address the problem of pain and opioid use in U.S. hemodialysis patient populations by a) initiating multipronged pain treatment tailored individually to each patient, without opioids, and b) using buprenorphine and other novel agents to reduce dependence on opioids in affected patients.

Justice Community Opioid Innovation Network (JCOIN) Methodology and Advanced Analytics Resource Center (U2C Clinical Trial Not Allowed)

Notice Number: RFA-DA-19-023
Letter of Intent Deadline: 30 days prior to the application due date
Application Deadline: February 27, 2019
Summary: Invites applications for a Methodology and Advanced Analytics Resource Center to support a national consortium of investigators examining promising interventions and other approaches that can improve the capacity of the justice system to effectively respond to the opioid epidemic.
Justice Community Opioid Innovation Network (JCOIN) Coordination and Translation Center (U2C Clinical Trial Optional)

Notice Number: RFA-DA-19-024  
Letter of Intent Deadline: 30 days prior to the application due date  
Application Deadline: February 27, 2019  
Summary: Invites applications for a Coordination and Translation Center to support a national consortium of investigators examining promising interventions and other approaches that can improve the capacity of the justice system to effectively respond to the opioid epidemic.

Justice Community Opioid Innovation Network (JCOIN) Clinical Research Centers (UG1 Clinical Trial Optional)

Notice Number: RFA-DA-19-025  
Letter of Intent Deadline: 30 days prior to the application due date  
Application Deadline: February 27, 2019  
Summary: Invites applications to establish Clinical Research Centers that enable a national consortium of investigators to examine promising interventions and other approaches that can improve the capacity of the justice system to effectively respond to the opioid epidemic.

Limited Competition: Behavioral Research to Improve MAT: Ancillary Studies to Enhance Behavioral or Social Interventions to Improve Adherence to Medication Assisted Treatment for Opioid Use Disorders (R01, Clinical Trials Optional)

Notice Number: RFA-AT-19-007  
Letter of Intent Deadline: February 13, 2019  
Application Deadline: March 15, 2019  
Summary: Seeks applications to expand research activities funded under RFA-AT-18-001, RFA-AT-18-002, and RFA-DA-18-005. Expansion of research activities should increase the generalizability of findings to allow for more rapid dissemination and implementation of successful interventions.

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional)

Notice Number: RFA-DA-18-020  
Letter of Intent Deadline: 30 days prior to the application due date  
Application Deadline: July 25, 2019 and July 25, 2020  
Summary: Supports outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of substance use disorders stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use.

Optimization of Non-addictive Therapies [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Not Allowed)

Notice Number: RFA-NS-19-010  
Letter of Intent Deadline: 30 days prior to the application due date  
Application Deadline: March 6, 2019  
Summary: Supports preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain.

Optimization of Non-addictive Therapies [Small Molecules and Biologics] to Treat Pain - (U44 Clinical Trial Not Allowed)

Notice Number: RFA-NS-19-020  
Letter of Intent Deadline: 30 days prior to the application due date  
Application Deadline: January 9, 2019 and March 6, 2019  
Summary: Supports preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain.
Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

Notice Number: RFA-NS-19-021

Letter of Intent Deadline: 30 days prior to the application due date

Application Deadline: February 1, 2019

Summary: Solicits cooperative agreement applications that propose clinical trials to test the comparative effectiveness of existing therapies or effectiveness of existing or novel approaches for prevention and management of pain while reducing risk of addiction. As detailed in the RFA, clinical trials addressing a wide-variety of pain conditions are sought. Note: Trials will be implemented at the Clinical and Translation Science Award (CTSA) Program hubs, which each may contain multiple clinical sites at different institutions, and/or any other clinical sites selected by the investigator that is not affiliated with the CTSA program. If you plan to apply, contact Frannie Horn (fhorn@uab.edu), who is the HEAL Initiative point-of-contact for the Center for Clinical and Translational Science (CCTS).

Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing (PRISM) (UG3/UH3, Clinical Trial Optional)

Notice Number: RFA-AT-19-004

Letter of Intent Deadline: 30 days prior to the application due date

Application Deadline: February 8, 2019

Summary: Encourages phased cooperative research applications to conduct efficient, large-scale pragmatic or implementation trials to improve pain management and reduce the unnecessary use of opioid medications.

Pragmatic Randomized Controlled Trial of Acupuncture for Management of Chronic Low Back Pain in Older Adults (UG3/UH3 Clinical Trial Required)

Notice Number: RFA-AT-19-005

Letter of Intent Deadline: 30 days prior to the application due date

Application Deadline: February 8, 2019

Summary: Encourages phased cooperative research applications to conduct an efficient, large-scale pragmatic trial to evaluate the impact of, and strategies to best implement, acupuncture treatment of older adults (65 years and older) with chronic low back pain.

Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 16–30) (UG3/UH3 Clinical Trial Required)

Notice Number: RFA-DA-19-035

Letter of Intent Deadline: 30 days prior to the application due date

Application Deadline: March 13, 2019

Summary: Seeks cooperative agreement applications to participate in the HEAL Preventing Opioid Misuse and Opioid Use Disorder in Older Adolescents and Young Adults (ages 16-30) initiative administered by NIDA.

Request for Administrative Supplements to Existing Grants to Accelerate Research on Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 16-30)

Notice Number: NOT-DA-19-003

Response Deadline: February 01, 2019

Summary: Announces the opportunity for NIDA investigators with relevant active research project grants and cooperative agreements to submit administrative supplements for funded projects to inform development of interventions and strategies to prevent opioid misuse and opioid use disorder in high-risk older adolescents and young adults (ages 16-30).
Sleep and Circadian-Dependent Mechanisms Contributing to Opiate Use Disorder (OUD) and Response to Medication Assisted Treatment (MAT) (R01 - Clinical Trial Not Allowed)
Notice Number: RFA-HL-19-028
Letter of Intent Deadline: January 27, 2019
Application Deadline: February 27, 2019
Summary: Invites applications that propose to elucidate basic sleep and circadian mechanisms closely-coupled to the risk of opiate use disorder, the pathobiology of opiate withdrawal, and that influence the response to medication-assisted treatment.

Sleep and Circadian-Dependent Mechanisms Contributing to Opiate Use Disorder (OUD) and Response to Medication Assisted Treatment (MAT) (U01 Clinical Trial Optional)
Notice Number: RFA-HL-19-029
Letter of Intent Deadline: January 27, 2019
Application Deadline: February 27, 2019
Summary: Invites applications that propose to elucidate basic sleep and circadian mechanisms closely-coupled to the risk of opiate use disorder, the pathobiology of opiate withdrawal, and that influence the response to medication-assisted treatment.

Stimulating Peripheral Activity to Relieve Conditions (SPARC): Anatomical and Functional Mapping of Pain-Related Visceral Organ Neural Circuitry (U01 Clinical Optional)
Notice Number: RFA-RM-19-001
Letter of Intent Deadline: 30 days prior to the application due date
Application Deadline: February 8, 2019
Summary: Invites applications proposing to map neural circuitry mediating visceral organ pain.

Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01 Clinical Trial Optional)
Notice Number: PAR-18-218
Letter of Intent Deadline: 30 days prior to the application due date
Application Deadline: March 27, 2019 and July 25, 2019
Summary: Supports research that advances compounds towards FDA approval by leveraging NIDA funds with the strengths and resources of outside organizations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, and small businesses.

Tissue Chips to Model Nociception, Addiction, and Overdose (UG3/UH3 Clinical Trial Not Allowed)
Notice Number: RFA-TR-19-003
Letter of Intent Deadline: January 28, 2019
Application Deadline: February 28, 2019
Summary: Provides funding for investigators to create and test devices that can model the mechanisms or effects of nociception/pain-relevant signaling, addiction, or opioid use disorders using human tissues in in vitro microphysiological systems.

Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed)
Notice Number: RFA-EB-18-003
Letter of Intent Deadline: 30 days prior to the application due date
Application Deadline: March 22, 2019; June 20, 2019; October 22, 2019; February 21, 2020; June 22, 2020; October 21, 2020; February 22, 2021
Summary: Supports support preclinical development and demonstration of safe, effective, and non-addictive device-based technologies and approaches to treat pain.
Translational Devices to Treat Pain (UG3/UH3 Clinical Trial Optional)

Notice Number: RFA-NS-19-016
Letter of Intent Deadline: 30 days prior to the application receipt date
Application Deadline: January 9, 2019; March 22, 2019; June 21, 2019; October 21, 2019; February 21, 2020; June 22, 2020; October 21, 2020; February 21, 2021
Summary: Encourages investigators to pursue translational activities and clinical trials to treat pain with innovative, targeted, and non-addictive diagnostic and/or therapeutic devices that improve patient outcomes and decrease or eliminate the need to prescribe opioids.

Translational Devices to Treat Pain (U44 Clinical Trial Optional)

Notice Number: RFA-NS-19-017
Letter of Intent Deadline: 30 days prior to the application receipt date
Application Deadline: January 9, 2019; March 22, 2019; June 21, 2019; October 21, 2019; February 21, 2020; June 22, 2020; October 21, 2020; February 21, 2021
Summary: Encourages small business concerns to pursue translational activities and clinical trials to treat pain with innovative, targeted, and non-addictive diagnostic and/or therapeutic devices that improve patient outcomes and decrease or eliminate the need to prescribe opioids.